This content is machine translated Heart failure in the light of the latest evidence MRAs offer advantages across the entire EF spectrum At the swissESCupdate, cardiology experts summarized important content from this year’s Annual Meeting of the European Society of Cardiology . In the area of heart failure, studies on the use…
View Post 8 min This content is machine translated Heart failure: ESC guideline update 2023 Therapy-relevant new evidence on the entire EF spectrum The update of the ESC guideline on the treatment of heart failure includedthe results of large randomized studies that were not published until after the guideline was published in 2021.…
View Post 14 min This content is machine translated Heart failure Interventional treatment of the tricuspid valve Long considered the “forgotten valve,” the tricuspid valve (TC) has gained increasing attention and recognition in recent years. This is due in no small part to the development of new… CME-Test
View Post 4 min This content is machine translated ESC guidelines on heart failure These are the new recommendations Numerous studies published in the last two years made it necessary to update the 2021 ESC Heart Failure Guidelines. In particular, this refers to new studies on SGLT2 inhibitors in…
View Post 10 min This content is machine translated GLP-1 agonists continue to gain ground Semaglutide in patients with obesity and heart failure It has long been known that the active ingredient class of glucagon-like peptide-1 agonists (GLP-1) reduces cardiovascular consequences in diabetics and leads to significant weight loss in patients with obesity.…
View Post 4 min This content is machine translated Heart failure (HFpEF) Is cardiac amyloidosis hiding behind it? In those over 65, heart failure is the most common reason for hospitalization. Clarification of the cause of the disease is essential to direct patients to targeted therapy. Patients with…
View Post 5 min This content is machine translated Heart failure in type 2 diabetes Success story of SGLT-2 inhibitors – impressive evidence base. The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart…
View Post 14 min This content is machine translated Heart failure Interventional treatment of the tricuspid valve Long considered the “forgotten valve,” the tricuspid valve (TC) has gained increasing attention and recognition in recent years. This is due in no small part to the development of new… CME-Test
View Post 6 min This content is machine translated Heart failure Dapagliflozin now approved in preserved ejection fraction [1,4]** After dapagliflozin had been approved for some time for heart failure with reduced ejection fraction, Swissmedic now granted an indication extension for heart failure with mildly reduced or preserved ejection…
View Post 8 min This content is machine translated Heart failure Ejection fraction as a therapy criterion Heart failure with reduced ejection fraction (HFrEF) is characterized by a left ventricular ejection fraction (LVEF) in the range ≤40% according to the current classification, whereas heart failure with preserved…
View Post 6 min This content is machine translated Suspected heart failure - what to do? Expert recommendations up-to-date According to the European Society of Cardiology (ESC) guideline updated last year, heart failure is classified into HFrEF, HFmrEF, and HFpEF according to left ventricular ejection fraction. Regarding drug therapy, early…
